The FDA approved tarlatamab for small cell lung cancer patients with limited options, tripling their life expectancy to a median of 14 months.
Dr. Anish Thomas called tarlatamab the first real hope in years for small cell lung cancer patients, while Dr. Timothy Burns deemed it practice-changing.
[
add
]
[
|
|
...
]